ORAL PHARMACEUTICALS TREATMENT

Brand Owner (click to sort) Address Description
ACTOS ME PAC Takeda Chemical Industries, Ltd. 1-1, Doshomachi 4-Chome, Chuo-Ku Osaka Japan Oral pharmaceuticals for the treatment of diabetes in individual doses contained in blister-packaging;PACK;
ACTOS SULF PAC Takeda Chemical Industries, Ltd. 1-1, Doshomachi 4-Chome, Chuo-Ku Osaka Japan Oral pharmaceuticals for the treatment of diabetes in individual doses contained in blister-packaging;PACK;
ARBACTIV Osmotica Holdings Corporation Edificio AFRA Avenida Samuel Lewis y Calle 5 Panama oral pharmaceuticals for treatment of neurological conditions;
MOBLISA Osmotica Holdings Corporation Edificio AFRA Avenida Samuel Lewis y Calle 5 Panama oral pharmaceuticals for treatment of neurological conditions;
MYPRO 12 Safe Breath International AB Östermalmsgatan 19 S-114 26 Stockholm Sweden Oral pharmaceuticals for the treatment of halitosis; prophylactic and therapeutic preparations for the treatment of halitosis; and medicated mouthwashes;Dentifrices; non-medicated mouthwashes; oral care products, namely toothpaste, non-medical dental rinse; non-medicated toiletries; and cleaning preparations;MY PRO TWELVE;12;
OSMAXIS Osmotica Holdings Corporation Edificio AFRA Avenida Samuel Lewis y Calle 5 Panama oral pharmaceuticals for treatment of neurological conditions;
OSMOLEX Osmotica Holdings Corporation Edificio AFRA Avenida Samuel Lewis y Calle 5 Panama oral pharmaceuticals for treatment of neurological conditions;
OSMOLEX Osmotica Holdings Corporation Edificio AFRA Avenida Samuel Lewis y Calle 5 Panama Oral pharmaceuticals for treatment of neurological conditions;
OSMOLEX ADAMAS PHARMA 1900 Powell Street, Suite 1000 Emeryville CA 94608 Oral pharmaceuticals for treatment of neurological conditions;
OSMOLEX ER ADAMAS PHARMA 1900 Powell Street, Suite 1000 Emeryville CA 94608 Oral pharmaceuticals for treatment of neurological conditions;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. The present invention generally relates to the treatment of uremic toxins in vivo using uremic toxin-treating enzymes, and/or cells capable of producing uremic toxin-treating enzymes or otherwise reacting with uremic toxins. Non-limiting examples of cases where the treatment of uremic toxins is desired include renal disease or dysfunction, gout, subjects receiving chemotherapy, or the like. In one aspect, the treatment includes an oral delivery composition able to reduce the blood concentration of one or more non-protein nitrogen compounds in vivo. The composition, in some cases, may comprise one, two, or more uremic toxin-treating enzymes, such as urease, uricase or creatininase. The oral delivery composition may be able to deliver the uremic toxin-treating enzymes, substantially undigested, to the intestines, where the enzymes can interact with uremic toxins transported to the intestines from the bloodstream. In another aspect, the treatment includes an oral delivery composition comprising a cell able to reduce the concentration of one or more uremic toxins in vivo. In some cases, the cell may be designed to overexpress one, two, or more uremic toxin-treating enzymes, such as urease, uricase or creatininase, for example, by transfecting the cell with a corresponding gene. In some embodiments, a species able to react with or otherwise sequester by-products of the uremic toxin-treating enzyme reactions may be included with the oral delivery composition. For example, if the by-product is ammonium, the species may be a sorbent able to adsorb ammonium, an enzyme able to react with the ammonium, or the like.